Untargeted Lipidomic Reveals Potential Biomarkers in Plasma Samples for the Discrimination of Patients Affected by Parkinson’s Disease DOI Creative Commons
Kateryna Tkachenko, J.M. González-Sáiz, C. Pizarro

и другие.

Molecules, Год журнала: 2025, Номер 30(4), С. 850 - 850

Опубликована: Фев. 12, 2025

Nowadays, the diagnosis of Parkinson's disease (PD) remains essentially clinical, based on subjective observations clinicians. In addition, misdiagnosis with other neuro disorders, such as Alzheimer's (AD), can occur. Herein, an untargeted lipidomic analysis 75 plasma samples was performed to identify lipid species capable discriminating between these two groups. Therefore, PLS-DA and OPLS-DA revealed significant differences in patient profiles sphingolipid glycerophospholipid categories. As a result, putative biomarker panel developed, which included HexCer (40:1; O2) PC (O-32:0), area under receiver operating characteristic curve (AUC) > 80, respectively. This effective diseased healthy subjects, but most importantly, it could discriminate neurodegenerative disorders that present similar symptoms, namely PD AD. Together, findings suggest dysregulated metabolism lipids plays critical role AD pathology may represent valuable clinical tool for their diagnosis. Thus, further targeted studies are encouraged better understand underlying mechanisms confirm diagnostic potency identified metabolites.

Язык: Английский

Untargeted Lipidomic Reveals Potential Biomarkers in Plasma Samples for the Discrimination of Patients Affected by Parkinson’s Disease DOI Creative Commons
Kateryna Tkachenko, J.M. González-Sáiz, C. Pizarro

и другие.

Molecules, Год журнала: 2025, Номер 30(4), С. 850 - 850

Опубликована: Фев. 12, 2025

Nowadays, the diagnosis of Parkinson's disease (PD) remains essentially clinical, based on subjective observations clinicians. In addition, misdiagnosis with other neuro disorders, such as Alzheimer's (AD), can occur. Herein, an untargeted lipidomic analysis 75 plasma samples was performed to identify lipid species capable discriminating between these two groups. Therefore, PLS-DA and OPLS-DA revealed significant differences in patient profiles sphingolipid glycerophospholipid categories. As a result, putative biomarker panel developed, which included HexCer (40:1; O2) PC (O-32:0), area under receiver operating characteristic curve (AUC) > 80, respectively. This effective diseased healthy subjects, but most importantly, it could discriminate neurodegenerative disorders that present similar symptoms, namely PD AD. Together, findings suggest dysregulated metabolism lipids plays critical role AD pathology may represent valuable clinical tool for their diagnosis. Thus, further targeted studies are encouraged better understand underlying mechanisms confirm diagnostic potency identified metabolites.

Язык: Английский

Процитировано

0